Investor Alert: Abbott Cooper PLLC Announces Investigation into Atea Pharmaceuticals, Inc.; Urges Atea Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, CT / ACCESSWIRE / September 19, 2023 / Abbott Cooper PLLC is investigating Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or the "Company") on behalf of the Company's investors.

The investigation seeks to determine whether Atea stockholders have been injured due to any violations of fiduciary duty or federal securities law in connection with (i) Atea's rejection of Tang Capital Partners' offer, made on behalf of Concentra Biosciences, to acquire all outstanding shares of Atea common stock for $5.75 plus a contingent value right and (ii) changes to Atea's advance notice bylaws that may have the effect of entrenching Atea's board of directors.

Atea stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing or visiting our website at for additional information about this investigation as well as their legal rights and options.

Abbott Cooper PLLC is dedicated to shareholders' rights and empowering shareholders through strategic counsel and legal advocacy. For additional information about Abbott Cooper PLLC, please visit


Abbott Cooper PLLC
J. Abbott R. Cooper, Esq.
(475) 333-0674

Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Abbott Cooper PLLC

View source version on

NOTE: This content is not written by or endorsed by "WSPA", its advertisers, or Nexstar Media Inc.

For inquiries or corrections to Press Releases, please reach out to Accesswire.